Lagardère, P.; Mustière, R.; Amanzougaghene, N.; Hutter, S.; Franetich, J.-F.; Azas, N.; Vanelle, P.; Verhaeghe, P.; Primas, N.; Mazier, D.;
et al. 4-Substituted Thieno[3,2-d]pyrimidines as Dual-Stage Antiplasmodial Derivatives. Pharmaceuticals 2022, 15, 820.
https://doi.org/10.3390/ph15070820
AMA Style
Lagardère P, Mustière R, Amanzougaghene N, Hutter S, Franetich J-F, Azas N, Vanelle P, Verhaeghe P, Primas N, Mazier D,
et al. 4-Substituted Thieno[3,2-d]pyrimidines as Dual-Stage Antiplasmodial Derivatives. Pharmaceuticals. 2022; 15(7):820.
https://doi.org/10.3390/ph15070820
Chicago/Turabian Style
Lagardère, Prisca, Romain Mustière, Nadia Amanzougaghene, Sébastien Hutter, Jean-François Franetich, Nadine Azas, Patrice Vanelle, Pierre Verhaeghe, Nicolas Primas, Dominique Mazier,
and et al. 2022. "4-Substituted Thieno[3,2-d]pyrimidines as Dual-Stage Antiplasmodial Derivatives" Pharmaceuticals 15, no. 7: 820.
https://doi.org/10.3390/ph15070820
APA Style
Lagardère, P., Mustière, R., Amanzougaghene, N., Hutter, S., Franetich, J.-F., Azas, N., Vanelle, P., Verhaeghe, P., Primas, N., Mazier, D., Masurier, N., & Lisowski, V.
(2022). 4-Substituted Thieno[3,2-d]pyrimidines as Dual-Stage Antiplasmodial Derivatives. Pharmaceuticals, 15(7), 820.
https://doi.org/10.3390/ph15070820